HighTide’s First NDA for Diabetes Drug HTD1801 Accepted by China’s NMPA

Hightide Therapeutics Inc ( (HK:2511) ) has provided an update.

HighTide Therapeutics said China’s National Medical Products Administration has accepted its first New Drug Application for HTD1801 to treat Type 2 diabetes, a key step toward commercializing the company’s lead asset. The filing underscores HighTide’s progress in translating its clinical pipeline into potential revenue-generating products, which could strengthen its competitive position in the crowded diabetes market if approval is ultimately secured.

The NDA follows three multicenter, randomized, double-blind, controlled Phase III trials in which HTD1801 met primary and multiple secondary endpoints and improved glycemic control, lipid metabolism, inflammatory markers, and renal function. These findings position HTD1801 as a potential single therapy addressing multiple facets of the cardiovascular-kidney-metabolic spectrum, which, if successfully brought to market, could offer differentiated value to patients and healthcare systems and support the company’s long-term growth trajectory.

The most recent analyst rating on (HK:2511) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Hightide Therapeutics Inc stock, see the HK:2511 Stock Forecast page.

More about Hightide Therapeutics Inc

HighTide Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for metabolic and related chronic diseases. The group’s pipeline includes HTD1801, an oral drug candidate targeting the cardiovascular-kidney-metabolic spectrum, with a particular focus on treating Type 2 diabetes mellitus in the China market and potentially beyond.

Average Trading Volume: 684,320

Technical Sentiment Signal: Sell

Current Market Cap: HK$1.35B

For detailed information about 2511 stock, go to TipRanks’ Stock Analysis page.